Gene therapy for aging: why progress is so slow

Gene therapy has existed for decades. It allows scientists to increase or decrease gene activity in specific cells. For longevity research, this is highly relevant: many proteins shift in concentration as we age, and some of those shifts measurably contribute to physical decline. The overview article on Fight Aging! explains why translating this science into practical treatments has proven so difficult.

The core problem is delivery. A gene therapy requires a carrier, typically a virus-like particle such as an AAV vector, to transport genetic material into cells. These carriers work well for small, accessible tissues: a muscle, a fat cell, or a brain region reached via the nose. But reaching most organs deep in the body requires direct injection, which is rarely acceptable outside the context of serious disease.

The liver as a bottleneck

Intravenous delivery is a more attractive option, but runs into a persistent obstacle: the liver captures the majority of particles before they reach their target. High doses can also trigger immune reactions. In recent years, deaths have been reported following systemic high-dose administration, significantly dampening enthusiasm for broad intravenous applications.

What does work

The most actively explored applications fall into a narrow category: converting a small number of fat cells into factories that produce a beneficial protein circulating throughout the body. Examples include klotho and follistatin, proteins associated with vitality in later life. These require only a small amount of vector, and that is achievable. The leap to simultaneously modifying cells throughout the entire body via a single injection is not feasible yet. Researchers see partial epigenetic reprogramming as a potential workaround, but technical hurdles there remain substantial as well.

Read the original article